Ekso Bionics shares rocket on FDA nod on exoskeleton for brain injury

Ekso Bionics climbs (EKSO +81.6%) is up big in early trade on a whopping 184x surge in volume in reaction to its announcement that the FDA has approved robotic exoskeleton EksoNR for use in patients with acquired brain injury (ABI), the first such device approved for this population.

EksoNR is the next-generation version of the company’s first robotic exoskeleton, approved in 2016 for stroke and spinal cord injury rehabilitation.

https://seekingalpha.com/news/3586180-ekso-bionics-shares-rocket-on-fda-nod-on-exoskeleton-for-brain-injury